No Data
No Data
JonesTrading Initiates Monopar Therapeutics(MNPR.US) With Buy Rating, Announces Target Price $2
Monopar Therapeutics Inc: Positioned for Growth With Strategic Radiopharmaceutical Pivot and Promising Preclinical Data
Monopar Therapeutics Begins Pioneering MNPR-101-Zr Trial
Express News | Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical Mnpr-101-Zr
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24
Monopar Therapeutics(MNPR.US) Officer Buys US$25,573.85 in Common Stock
No Data